Abstract. Nuclear receptors are ligand-dependent transcription factors that recently have been shown to play important roles in the metabolism of cholesterol and bile acids. Cholesterol homeostasis is maintained by de novo synthesis, absorption from diet, catabolism to bile acids and other steroids, and excretion into bile. Dysregulation of this mechanism leads to atherosclerosis and its life-threatening coronary and cerebrovascular sequelae. Conversion of cholesterol to bile acids in the liver is positively regulated by liver X receptor (LXR) a, a nuclear receptor for oxysterols. LXRa and LXRb, a second oxysterol receptor, regulate intestinal absorption and biliary excretion of cholesterol by inducing target gene expression. LXRs stimulate reverse cholesterol transport from peripheral tissues and exhibit antiatherogenic activity. Farnesoid X receptor (FXR), a bile acid receptor, represses bile acid synthesis and import in hepatocytes, stimulates bile acid export from cells, and protects hepatocytes from bile acid toxicity. Pregnane X receptor (PXR) and vitamin D receptor (VDR) respond to secondary bile acids and induce their catabolism. Thus, nuclear receptors play important roles in regulation of cholesterol and bile acid metabolism.
Introduction
Nuclear receptors are ligand-inducible transcription factors that are involved in many biological processes including cell growth and differentiation, embryonic development, and metabolic homeostasis (1) . The transcriptional activity of nuclear receptors is modulated by ligands such as steroids, retinoids, and other lipidsoluble compounds. Upon ligand binding, nuclear receptors undergo a conformational change that results in the dissociation of corepressors and recruitment of coactivators (2) . These cofactors form complexes with associated chromatin remodeling factors and recruit the basal transcription machinery. Cofactor interactions allow nuclear receptors to modulate transcription of specific target genes. Forty-eight human nuclear receptors have been identified, and one third of them have no characterized ligands (known as orphan receptors) (Table 1) . Recently, nuclear receptors belonging to the NR1H and NR1I subfamilies have been shown to control cholesterol and bile acid metabolism.
Cholesterol is an essential compound in all eukaryotic organisms. It serves as a precursor of steroids such as corticosteroids, sex hormones, vitamin D, and bile acids and serves as an essential structural component of cell membranes (3) . Atherosclerosis is due to the accumulation of excess cholesterol and results in life-threatening coronary and cerebrovascular disease. The liver X receptors (LXRs) are nuclear receptors that act as cholesterol sensors and regulate cholesterol metabolism. Bile acids are the major metabolites of cholesterol in the body, and they are essential for the solubilization and absorption of dietary cholesterol and fat-soluble vitamins (4) . Bile acids are detergents and can cause liver dysfunction and colon carcinogenesis at superphysiological concentrations (5) . Farnesoid X receptor (FXR) (NR1H4), pregnane X receptor (PXR) (NR1I2), and vitamin D receptor (VDR) (NR1I1) are bile acid receptors that regulate bile acid metabolism. As homeostatic switches in lipid metabolism, nuclear receptors control the concentration of "double-edged sword" chemicals.
LXRs and cholesterol metabolism
The LXR subfamily consists of two members, LXRa (NR1H3) and LXRb (NR1H2), both of which were cloned as orphan receptors (6) . While LXRb is ubiquitously expressed, LXRa is mainly localized in liver, adipose tissue, intestine, kidney, and macrophages. LXRa and LXRb were found to be activated by oxysterols such as 22(R)-hydroxycholesterol, an intermediate in adrenal steroidogenesis, and 24(S),25-epoxycholeserol, which is formed in the liver via a shunt in the cholesterol biosynthetic pathway (7 -9) (Fig. 1) . Both LXRs heterodimerize with the retinoid X receptor (RXR) (NR2B), which is activated by 9-cis-retinoic acid ( Table 1) . The RXR-LXRa and RXR-LXRb heterodimers preferentially bind to a DNA response element that consists of two hexanucleotide direct repeat motifs separated by 4 nucleotides (DR-4). These heterodimers function as permissive heterodimers, in that they can be activated by ligands for LXRs or RXR (7) .
Cholesterol homeostasis is maintained by de novo synthesis, dietary absorption, catabolism to bile acids and steroid hormones, and biliary excretion (Fig. 2) . The liver serves as the primary site for the biosynthesis and elimination of cholesterol. In the hepatocyte, cholesterol biosynthesis is regulated by a proteolytic mechanism involving the sterol regulatory element-binding protein (SREBP) family transcription factors (10) . When cholesterol is present in the diet at levels surpassing the biosynthetic rate, SREBP is inactive, biosynthesis is inhibited, and synthetic intermediates accumulate. One intermediate, squalene, is subsequently metabolized to 24(S),25-epoxycholesterol in a shunt pathway. LXRa is activated by 24(S),25-epoxycholesterol and induces the expression of genes that mediate bile acid synthesis and excretion of cholesterol into bile. In rodents, LXRa stimulates transcription of CYP7A1, the rate-limiting enzyme in the classic bile acid biosynthetic pathway, by binding to a DR-4 element in its promoter region (8) .
The ATP-binding cassette (ABC) transporters ABCG5 / ABCG8 mediate biliary excretion of cholesterol (11) . The expression of ABCG5 and ABCG8 is also induced by LXRa activation, although LXR-binding elements have not been identified in these genes (12) . Toxic levels of cholesterol accumulate in the livers of Lxra -null mice fed a high cholesterol diet due to a loss of induction of CYP7A1, ABCG5, and ABCG8 expression (8, 12) . Although LXRb is expressed in the liver, its hepatic function appears to be limited. Lxrb-null mice tolerate increased dietary cholesterol as effectively as wild-type mice (13) . Interestingly, the expression of the human CYP7A1 gene is not regulated by LXRa due to a mutation in the DR-4 promoter element (14) . In addition to hepatic regulation of bile acid synthesis, LXRs modulate cholesterol absorption in the intestine. Experiments utilizing Lxra -/ -
/Lxrb
-/ -mice reveal that LXR activation represses cholesterol absorption (15) . Since the expression of ABCA1, an ABC transporter mutated in Tangier disease, is induced by LXR activation, it was hypothesized that ABCA1-catalyzed efflux might account for the associated decrease in cholesterol absorption (15) . The findings that ABCA1 is dominantly expressed on the basolateral surface of intestinal cells (16) and that the effect of an LXR agonist on fecal cholesterol loss is observed in Abca1-null mice (17) argue against this hypothesis. Subsequently, other ABC sterol transports, ABCG5 and ABCG8, were demonstrated to mediate the LXR agonist-mediated reduction of cholesterol absorption (18) . ABCG5 and ABCG8 are expressed in the intestine, are localized to the apical membrane of cells (19) , and are LXR target genes (12) . Taken together, recent studies show that LXRs play an important role in cholesterol metabolism by regulating catabolism to bile acids, excretion to bile, and intestinal absorption (Fig. 2) .
Reverse cholesterol transport involves the transport of excess cholesterol from peripheral cells to the liver via nascent high-density lipoprotein (HDL). HDL-bound cholesterol is taken up by the liver for biliary secretion and fecal excretion. ABCA1 is critical for the efflux of excess cellular cholesterol to apolipoprotein (Apo) acceptors such as ApoA-I, the first step in reverse cholesterol transport (20) . Mutations in the ABCA1 gene have been identified in Tangier disease, a syndrome characterized by the absence of plasma HDL, accumulation of cholesterol in the peripheral tissues, and atherosclerosis. LXRs bind to a DR-4 element in the promoter of the ABCA1 gene (21) and LXR activation stimulates ApoA-I mediated cholesterol efflux (22) . Lxra 
-/ -mice developed more atherosclerotic lesions than mice that were transplanted with wild-type bone marrow (25) . Thus, LXRs exert antiatherogenic effects by stimulating reverse cholesterol transport (Fig. 2) . Peroxisome proliferator-activated receptor g (PPARg) (NR1C3) ligands were reported to inhibit atherosclerosis in Ldlr-null mice (26) . LXRa was determined to be a PPARg target gene and PPARg induces ABCA1 through induction of the LXR pathway (27) . The expression of ApoE, which is also involved in reverse cholesterol transport, is regulated by LXRs in macrophages and adipocytes (28) . LXRs have also been shown to induce the expression of several enzymes that act on lipoproteins, including lipoprotein lipase, cholesterol ester transfer protein, and phospholipid transfer protein (20) . The role of these enzymes in reverse cholesterol transport is not yet clear. Recently, LXR activation was reported to inhibit inflammatory gene expression in the aortas of atherosclerotic mice (29) . Therefore, the LXR pathway inhibits the development of atherosclerosis by regulating a program of metabolic and inflammatory genes.
In addition to their role in maintaining cholesterol homeostasis, LXRs also regulate fatty acid metabolism (Fig. 2) . Administration of synthetic LXR agonists to mice induces expression of fatty acid biosynthetic genes, such as acetyl CoA carboxylase, fatty acid synthase, and stearyl CoA desaturase-1, and results in increased liver and plasma triglycerides and phopholipids (30) . LXRs regulate expression of SREBP-1c, a transcription factor that enhances the expression of genes involved in fatty acid biosynthesis (20) . LXRs also activate fatty acid synthase and angiopoietin-like protein 3, a liver-specific secretory protein that inactivates lipoprotein lipase and increases plasma triglyceride levels (20, 31) . Because LXRs have both antiatherogenic and lipogenic activities, the development of LXR agonists that regulate cholesterol metabolism without causing hypertriglycemia is of great pharmacological interest. Recently, we found that phytosterol-derived LXR agonists inhibit intestinal cholesterol absorption without increasing plasma triglyceride levels (32) . It is suggested that phytosterol derivatives reduce intestinal sterol absorption by inducing the expression of ABCG5 and ABCG8, which might excrete these compounds from mucosal cells, and prevent them from stimulating hepatic LXRs. Furthermore, LXRs have also been found to regulate glucose metabolism (33) . LXRs may be key regulators of lipid and glucose metabolism and are promising molecular targets in therapies for metabolic diseases.
Nuclear receptors and bile acid metabolism
Bile acids are end products of hepatic cholesterol catabolism. The primary bile acids cholic acid and chenodeoxycholic acid are derived via several intermediate steps from cholesterol and are secreted in bile as glycine or taurine conjugates (4). They function as solubilizing detergents and play an important role in the digestion and absorption of lipids in the small intestine. Most bile acids are reabsorbed in the intestine and recirculate to the liver through the portal vein, a mechanism called the enterohepatic circulation (Fig. 3) . Bile acids that escape reabsorption are converted to the secondary bile acids deoxycholic acid and lithocholic acid by the intestinal microflora (5) . A portion of the secondary bile acids enter the enterohepatic circulation pathway. Bile acids produce toxic effects at high concentrations, and secondary bile acids, especially lithocholic acid, are thought to participate in the pathogenesis of liver disease and colon cancer (5) . Lithocholic acid induces DNA strand breaks, forms DNA adducts, inhibits DNA repair enzymes, and can promote colon cancer in rodent models. The bile acid-responding nuclear receptors FXR, PXR, and VDR prevent toxicity by regulating bile acid metabolism (Fig. 3) .
FXR was originally identified as a receptor activated by farnesol, an intermediate in cholesterol synthesis, and juvenile hormone III, an insect hormone. Sequent studies revealed a major role of FXR as a bile acid receptor (34) . It is expressed in liver, intestine, kidney, and the adrenal gland; heterodimerizes with RXR; and responds to both primary and secondary bile acids. Among the major bile acids, chenodeoxycholic acid is the most potent FXR agonist (Fig. 1) . Bile acid-liganded FXR represses the expression of CYP7A1 and CYP8B, enzymes involved in hepatic bile acid synthesis, through an indirect pathway. FXR induces the transcription of small heterodimer partner (SHP) (NR0B2), an atypical nuclear receptor that binds to liver receptor homolog-1 (LRH-1) (NR5A2) and blocks its function (35) . FXR was also reported to suppress CYP7A1 expression by inducing the expression of fibroblast growth factor-19 (36) . FXR induces the expression of bile acid-exporting ABC transporters in hepatocytes, including bile salt export pump (ABCB11) and multidrug resistanceassociated protein 2 (ABCC2) (37, 38) . The expression of sodium / taurocholate cotransporting polypeptide, which is the principal bile acid uptake protein in liver, is repressed by FXR activation through a SHP-dependent mechanism (39) . Fxr-null mice have impaired resistance to bile acid-induced hepatotoxicity (40) , and a synthetic FXR agonist exerts hepatoprotection in animal models of intra-and extrahepatic cholestasis (41) . Taken together, these recent works show that FXR suppresses the synthesis and import of bile acids in hepatocytes and stimulates their biliary excretion, resulting in protection of hepatocytes from bile acid toxicity. In the intestine, FXR activation induces the expression of the intestinal bile acid-binding protein, a mediator of enterohepatic circulation of bile acids (34) (Fig. 3) .
PXR and VDR, both of which form heterodimers with RXR (Table 1) ; sense the concentration of secondary bile acids, including lithocholic acid (Fig. 1) ; and induce their metabolism in the liver and intestine (42 -44) (Fig. 3) . A key PXR and VDR target gene is CYP3A, which converts lithocholic acid to the non-toxic hyodeoxycholic acid. Further evaluation of the physiological roles of PXR and VDR in bile acid metabolism awaits future investigation.
Perspectives
Nuclear receptors including LXRs, FXR, PXR, and VDR play important roles in the control of cholesterol and bile acid metabolism. Individual receptors have the potential to respond to several ligands (e.g., VDR to 1a ,25-dihydroxyvitamin D 3 and lithocholic acid) and induce various sets of target genes. Ligand-selective mechanisms of target gene induction remain elusive. While both neurosteroids and LXRs are abundant in the brain, the physiological function of LXRs in the brain is poorly understood. Continued study of nuclear receptor regulation of dynamic metabolic homeostasis in normal physiology and in the context of human disease promises to provide novel drug targets for metabolic diseases. 
